OUTSOURCED PHARMA CAPACITY UPDATE SMALL MOLECULE VIDEOS
Upperton Pharma Solutions Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form
Ian Lafferty, CTO, and Josh Moule, Business Development Manager, talk through Upperton’s capabilities, project management approach and provide a virtual tour of their 60,000 sq. ft development and manufacturing facility.
Quotient Sciences Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form
Compressed timelines pose challenges, ranging from limited API supply to clinical trial logistics. Explore how expedited review pathways can be strategically used to accelerate development while mitigating CMC risks.
PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form
Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.
Your Boutique CDMO Partner Of Choice
Lora Wallis and Chris Cuthbertson highlight Douglas CDMO’s strengths in high-potency softgels and liquids and the company's 67 years of expertise and a client-centric approach.
Comprehensive CDMO Services From Clinical To Commercial Supply
Bora Pharmaceuticals specializes in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, and sterile injectable products.
MilliporeSigma Capacity Update July 2025: Small Molecule Drug Substance/API
Applications specialist John Stevens shows how MilliporeSigma is using their 35+ years of CDMO experience and expertise to move customers’ small molecules forward to the clinic and beyond to commercialization.
Amorphous Solid Dispersions: Pre-Clinical To Commercial Capabilities
ASDs continue to be an attractive option for progressing and commercializing poorly soluble compounds. This talk focuses on capabilities to screen the potential for ASDs in early phase studies as well as their commercial applicability.
Your Integrated Drug Substance Partner
With capabilities to support your next small molecule drug substance program from R&D to commercial scale, learn about our integrated facilities, project teams, and available capacity.
Aragen Capacity Update July 2025: Small Molecule Drug Substance/API
Explore specialized expertise in solving challenging small molecule formulation problems (poor solubility, bioavailability, complex delivery routes).
Cambrex Capacity Update April 2025: Small Molecule
Chief Scientific Officer of Cambrex and President of Snapdragon Chemistry, Matthew Bio, Ph.D., presents the company’s capabilities in the development of peptide therapeutics.
Bend Bioscience Capacity Update April 2025: Small Molecule
Leverage expert small molecule solutions from preclinical development to commercial manufacturing, with strengths in large-scale oral solids, advanced formulations, and more.
SK pharmteco Capacity Update April 2025: Small Molecule
Join Nicholas Duda, Executive Director of Business Development, as he highlights our available capacity across North America, Europe, and Asia, and our unique capabilities.
Ropack Pharma Solutions Capacity Update April 2025: Small Molecule
Learn how our nearly 50 years of expertise in oral solid dosage manufacturing and packaging can support your project with cutting-edge services and expanding capacity to meet your needs.
Upperton Pharma Solutions Capacity Update January 2025: Small Molecule
Gain insight into the capabilities of our award-winning development and manufacturing facility, which features 10 state-of-the-art GMP manufacturing suites integrated with cutting-edge R&D and QC laboratories.
Douglas CDMO Capacity Update January 2025: Small Molecule
By leveraging our extensive experience, flexible capabilities, and client-focused approach, we help our partners accelerate time-to-market and achieve successful outcomes for their therapies.
Alcami Capacity Update January 2025: Small Molecule
With cutting-edge capabilities and client-focused solutions, Alcami supports your drug development journey from concept to commercialization, helping you bring transformative therapies to patients with speed and quality.
Ajinomoto Bio-Pharma Services Capacity Update January 2025: Small Molecule
Discover how our cutting-edge development laboratories, advanced flow chemistry units, and expanded manufacturing capacity are designed to address your most complex challenges and fulfill all your production needs.
SK pharmteco Capacity Update October 2024: Small Molecule
Witness how our 80 years of industry experience and a global capacity of ~1,000 m³ can provide scalable, high-quality solutions to support your small molecule programs.
Singota Solutions Capacity Update October 2024: Small Molecule
With advanced infrastructure and a comprehensive approach, see why we're well-positioned to support the development of stable, effective, and safe injectable products for advanced therapeutics.
PCI Pharma Capacity Update October 2024: Small Molecule
Discover how our recent investments have expanded our capacity for developing, manufacturing, and packaging highly potent drug products, leveraging over 35 years of expertise.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?